Companies › Nanjing RegeneCore Biotech
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Respiratory, Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RC1416 | – | Phase 2 | Moderate to Severe Asthma; Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Oct 2027 |
| RJK-RT2831 | – | Phase 1 | Hematologic Malignancies | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07403487 | RC1416 | Phase 2 | Moderate to Severe Asthma | Respiratory | Oct 2027 |
| NCT06756451 | RJK-RT2831 | Phase 1 | Hematologic Malignancies | Oncology | Apr 2028 |
| NCT07402551 | RC1416 | Phase 2 | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | May 2028 |
No annotated target.
–
SPARK Biopharma NuvOx ImmuneOncia Therapeutics MiNK Therapeutics Guangzhou JOYO Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.